Exagen Q2 Revenue Jumps 14 Percent

Exagen (NASDAQ:XGN), a diagnostics company focused on autoimmune conditions, released its second quarter results on July 29, 2025, for the quarter ending June 30. The main headline: revenue (GAAP) beat expectations, climbing to $17.2 million due to expanding sales of its flagship AVISE CTD test, but net loss (GAAP) widened year over year to $4.4 million, and operating expenses rose. Analyst consensus predicted $16.31 million in GAAP revenue and GAAP EPS (earnings per share) of $(0.15), but the EPS (GAAP) result was more negative than expected at $(0.21). The quarter demonstrated robust commercial momentum but highlighted persistent losses as investment in sales, research, and reimbursement efforts continues. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Exagen is a diagnostics company specializing in laboratory tests for autoimmune disorders such as lupus and rheumatoid arthritis. Its main product, AVISE CTD, is a panel of biomarker-based blood tests that help doctors diagnose connective tissue diseases earlier and more accurately. The test accounts for approximately 90% of current annual revenue, underpinning the company's financial results and growth strategy.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool